FIELD: biotechnology.
SUBSTANCE: described is the use of a variant of HIV splicing with SEQ ID NO 1 as a biomarker of HIV infection or the effectiveness of therapeutic treatment of HIV infection, as a biomarker for assessing the biological effect of a compound in treating HIV infection or a biomarker for screening a compound or a vaccine in preventing and/or treating HIV infection. Described is a corresponding method of treating HIV infection, which uses a variant of HIV splicing with SEQ ID NO 1 as a biomarker of HIV infection or therapeutic effectiveness.
EFFECT: obefazimod ABX464 alters viral RNA splicing, but not cellular splicing, and induces splicing of long non-coding RNA in locus miR-124, which leads to intensified regulation of anti-inflammatory miR124.
19 cl, 9 dwg, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MICRORNA-124 AS BIOMARKER | 2014 |
|
RU2687366C2 |
| QUINOLINE DERIVATIVES FOR USE IN TREATMENT OR PREVENTION OF CANCER | 2019 |
|
RU2811417C2 |
| COMPOSITIONS AND METHODS OF TREATING, PREVENTING AND REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDERS | 2020 |
|
RU2812903C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN 1 FOR PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA | 2016 |
|
RU2770021C2 |
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF KIDNEY CANCER | 2017 |
|
RU2752322C2 |
| METHODS FOR CLASSIFYING PATIENTS WITH SOLID CANCER | 2017 |
|
RU2745730C2 |
| AN ANTI-TUMOUR COMPOSITION | 0 |
|
SU1836103A3 |
| CANCER IMMUNOTHERAPY | 2014 |
|
RU2744194C2 |
| TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF | 2013 |
|
RU2661104C2 |
| METHODS AND COMPOSITIONS FOR TREATING TUMORS | 2017 |
|
RU2741786C2 |
